PTX-100 shows encouraging efficacy signals and safety in area of high unmet clinical need
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage...
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage...
Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy...
COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by...
Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving...
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is guided by its mission to develop novel, personalised therapies for...
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to...
Stockhead’s Year in Review video series is a yearly wrap up address from company leaders...
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a...
Prescient Therapeutics (ASX:PTX), an Australian biotech player developing personalised medicine therapies for cancer, has published...
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.